Clinical Trials Logo

Pancreas Ductal Adenocarcinoma clinical trials

View clinical trials related to Pancreas Ductal Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT04793932 Recruiting - Clinical trials for Pancreas Ductal Adenocarcinoma

Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)

CASSANDRA
Start date: November 3, 2020
Phase: Phase 2
Study type: Interventional

The main aim of this study is to compare the efficacy of short-course versus long-course pre-operative chemotherapy with PAXG or mFOLFIRINOX in patients who receive a diagnosis of pancreatic ductal adenocarcinoma (PDAC) resectable or borderline resectable.

NCT ID: NCT04662879 Enrolling by invitation - Diabetes Mellitus Clinical Trials

Early Detection Initiative for Pancreatic Cancer

EDI
Start date: October 14, 2021
Phase: N/A
Study type: Interventional

The Early Detection Initiative for Pancreatic Cancer is a multi-center randomized controlled trial to determine if algorithm-based screening in patients with new onset hyperglycemia and diabetes can result in earlier detection of pancreatic ductal adenocarcinoma.

NCT ID: NCT02723331 Active, not recruiting - Pancreatic Cancer Clinical Trials

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Start date: December 30, 2016
Phase: Phase 2
Study type: Interventional

The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).